全球特药合作与协议（2020-2026）

本报告调查并分析了全球特药产业的合作协议，详细阐述如何建立合作关係，以促进特药的研发、商业化和分销。

目录

摘要整理

第一章：引言

第二章：特药合约趋势

• 引言
• 过去几年的特药合作状况
• 最活跃的特药合约公司
• 特药合作：依合约类型划分
• 特药合作：依治疗领域划分
• 特药合作：依技术类型划分
• 特药合作的合约条款
  • 特药合作的金额概览
  • 特药合约的预付款
  • 特药合约的里程碑付款
  • 特药的特许权使用费率药品

第三章：主要专科药品合约

• 引言
• 依价值排名的顶级专科药品合约

第四章：最活跃的专科药品合约公司

• 引言
• 最活跃的专科药品合约公司
• 最活跃的专科药品合作伙伴公司简介

第五章：专科药品合约目录

• 引言
• 专科药品合约目录

第六章：专科药品合约：依技术类型分类

附录

Benchmark Partnering Strategies Across the Specialty Pharmaceutical Sector

Free report sample

The Global Specialty Pharmaceutical Partnering Terms and Agreements report provides a comprehensive analysis of partnering agreements across the global specialty pharmaceutical industry. Designed for business development, licensing, and corporate strategy professionals, the report delivers detailed insight into how companies structure partnerships to develop, commercialize, and distribute specialty pharmaceutical products.

The report analyzes specialty pharmaceutical agreements announced since 2020, offering a detailed view of how companies collaborate across research, development, licensing, and commercialization partnerships.

Through a combination of deal data, financial benchmarking, and access to real contract documents, the report allows users to understand how and why companies enter specialty pharmaceutical partnerships and what financial and contractual terms define these agreements.

Each deal entry links to a detailed online deal record and, where available, the underlying contract document filed with regulators, providing direct access to the contractual terms negotiated between partners.

Key Benefits

• Save Significant Research Time

Access a consolidated resource covering hundreds of specialty pharmaceutical agreements rather than searching multiple press releases, filings, and industry databases.

• Benchmark Specialty Pharma Deal Structures

Understand how companies structure specialty pharmaceutical partnerships, including collaboration, licensing, development, and commercialization arrangements.

• Analyze Financial Deal Terms

Review available data on headline deal values, upfront payments, milestone payments, and royalty structures to benchmark financial terms across comparable agreements.

• Access Real Contract Documents

Where available, explore actual partnership agreements filed with regulators, enabling detailed analysis of the contractual provisions behind real-world deals.

• Identify the Most Active Specialty Pharmaceutical Dealmakers

Discover which companies are leading partnering activity and analyze their collaboration strategies.

• Track Industry Trends

Analyze specialty pharmaceutical partnering activity since 2020 across technologies, therapeutic areas, and development stages.

What's Included in the Report

Analysis of specialty pharmaceutical dealmaking trends since 2020

Overview of partnering structures and financial models used in specialty pharma collaborations

Review of leading specialty pharmaceutical deals by disclosed value

Profiles of the most active specialty pharmaceutical dealmakers

Detailed analysis of deals organized by company, stage of development, therapy area, and technology type

A comprehensive directory of specialty pharmaceutical partnerships

Links to online deal records and contract documents where available

Deals are indexed in multiple ways-including company A-Z, deal value, development stage, technology type, and therapy target-making it easier to identify comparable transactions.

Due Diligence Insights from Real Agreements

By reviewing actual partnering contracts, the report enables users to evaluate key provisions such as:

• Rights granted or licensed under the agreement
• Financial payment structures and royalty terms
• Intellectual property ownership and licensing scope
• Development and commercialization responsibilities
• Exclusivity provisions and territorial rights
• Contract duration and termination clauses
• Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or summary deal databases.
• Why This Report Matters
• Specialty pharmaceuticals represent one of the fastest-growing segments of the life sciences industry, with companies increasingly relying on strategic partnerships to develop and commercialize innovative therapies.
• By combining comprehensive deal data, financial benchmarking, and access to real contract agreements, this report provides the intelligence needed to evaluate partnership opportunities, benchmark deal terms, and negotiate more effective specialty pharmaceutical collaborations.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in specialty pharmaceutical dealmaking

• 2.1. Introduction
• 2.2. Specialty pharmaceutical partnering over the years
• 2.3. Most active specialty pharmaceutical dealmakers
• 2.4. Specialty pharmaceutical partnering by deal type
• 2.5. Specialty pharmaceutical partnering by therapy area
• 2.6. Specialty pharmaceutical partnering by technology type
• 2.7. Deal terms for specialty pharmaceutical partnering
  • 2.7.1 Specialty pharmaceutical partnering headline values
  • 2.7.2 Specialty pharmaceutical deal upfront payments
  • 2.7.3 Specialty pharmaceutical deal milestone payments
  • 2.7.4 Specialty pharmaceutical royalty rates

Chapter 3 - Leading specialty pharmaceutical deals

• 3.1. Introduction
• 3.2. Top specialty pharmaceutical deals by value

Chapter 4 - Most active specialty pharmaceutical dealmakers

• 4.1. Introduction
• 4.2. Most active specialty pharmaceutical dealmakers
• 4.3. Most active specialty pharmaceutical partnering company profiles

Chapter 5 - Specialty pharmaceutical contracts dealmaking directory

• 5.1. Introduction
• 5.2. Specialty pharmaceutical contracts dealmaking directory

Chapter 6 - Specialty pharmaceutical dealmaking by technology type

Appendices

• Appendix 1 - Specialty pharmaceutical deals by company A-Z
• Appendix 2 - Specialty pharmaceutical deals by stage of development
• Appendix 3 - Specialty pharmaceutical deals by deal type
• Appendix 4 - Specialty pharmaceutical deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Specialty pharmaceutical partnering since 2020
• Figure 2: Active specialty pharmaceutical dealmaking activity since 2020
• Figure 3: Specialty pharmaceutical partnering by deal type since 2020
• Figure 4: Specialty pharmaceutical partnering by disease type since 2020
• Figure 5: Specialty pharmaceutical partnering by technology type since 2020
• Figure 6: Specialty pharmaceutical deals with a headline value
• Figure 7: Specialty pharmaceutical deals with an upfront value
• Figure 8: Specialty pharmaceutical deals with a milestone value
• Figure 9: Specialty pharmaceutical deals with a royalty rate value
• Figure 10: Top specialty pharmaceutical deals by value since 2020
• Figure 11: Most active specialty pharmaceutical dealmakers since 2020